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An analytical method based on isocratic reverse phase high-performance liquid chromatography was developed and validated
for the separation and quantiﬁcation of eight antidiabetic drugs: rosiglitazone, pioglitazone, glipizide, gliclazide, repaglinide,
nateglinide, glibenclamide, and glimepiride for their application in human plasma assay. Metformin is used as internal standard.
Analysis was done on Onyx monolithic C18 column (100 × 4.6mm, i.d., 5μm) using a mixture of 0.05% formic acid in water
and methanol in the ratio of 42:58(v/v) ﬁxed at a ﬂow rate of 0.5mL/min, and they were monitored at 234nm. Separation was
achieved in less than 20min. The calibration curves were linear in the range of 50–2000ng/mL. The method was validated for
its recovery, intra- and interday precision, stability, speciﬁcity, and selectivity. Plasma samples were prepared using solid-phase
extraction of analytes. Hence, the developed method was found to be suitable for the routine analysis of selected antidiabetic drugs
in biological matrices.
1.Introduction
Diabetes mellitus is a heterogeneous group of disorders char-
acterizedbyabnormalitiesincarbohydrate,protein,andlipid
metabolism [1]. The central disturbance in diabetes mellitus
is an abnormality in insulin production or action or both,
although other factors can be involved. This results primarily
in elevated fasting and postprandial blood glucose levels.
In recent years, diabetes mellitus has become a common
disease aﬀecting human health seriously. There are estimated
150 million people worldwide suﬀerings from diabetes, this
number may probably double by the year 2030. Reports
from the World Health Organization (WHO) indicate that
diabetes mellitus is one of the major killers of our time,
with people in South East Asia and Western Paciﬁc being
most at risk. Therefore, the human population worldwide
appears to be in the midst of an epidemic of diabetes.
About 90% of diabetes patients are found to be aﬀected
with type II (non-insulin-dependent) diabetes mellitus. It
is especially important to ensure the quality of antidiabetic
drugs for type II in which insulin deﬁciency is less severe.
All anti-diabetic drugs (structures shown Figures 1(a), 1(b),
1(c), 1(d), 1(e), 1(f), 1(g),a n d1(h)) chosen in this study
are commonly used in clinic for type II diabetes mellitus
patients. Thiazolidinedione class of drugs (Rosiglitazone
(ROS) and Pioglitazone (PIO)) exert their glucose-lowering
eﬀect by binding to peroxisome proliferator-activated recep-
tors gamma (PPARγ), thus increasing the receptor sensitiv-
ity to insulin [2–4]. Sulfonylurea drugs (Glipizide (GLP),
Gliclazide (GLC), Glibenclamide (GLB), and Glimepiride
(GLM)) act by increasing the secretion of insulin by the
functioning β cells of the pancreas. This generation of
hypoglycemic drugs are much more potent and are therefore
eﬀective at much lower dosages [5]. Repaglinide (REP) also
acts by stimulating insulin secretion of β cells, but it binds
to sites distinct from the sulfonylurea binding sites [6]a n d
Nateglinide (NGL), functions by increasing pancreatic β-
cell sensitivity to ambient glucose without increasing basal
insulin secretion [7, 8].
In the literature survey, HPLC gradient method for
six anti-diabetic drugs in human plasma [9], an isocratic2 ISRN Pharmaceutics
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Figure 1: Structural representation of Rosiglitazone (ROS), Pioglitazone (PIO), Glipizide (GLP), Gliclazide (GLC), Repaglinide (REP),
Nateglinide (NGL), Glibenclamide (GLB), and Glimepiride (GLM).
method for counterfeit drugs in pharmaceutical formula-
tions [10], and an HPLC method in human plasma for
metformin with three sulfonylurea drugs glibenclamide,
glipizide, and gliclazide [11] were reported along with few
other LC-MS, HPLC, and HPTLC methods conﬁned to
single or two drugs in combination [12–27].
The present paper describes an isocratic method for the
separation and quantiﬁcation of eight anti-diabetic drugs
using reverse phase HPLC-UV, as the usage of combination
of thiazolidinediones and sulfonyl ureas was found to be
successful in the treatment of type II diabetes, the method
would help in assay of drugs in a single run which reduces
the time of analysis and does not require separate methods
for each drug. The developed method was also validated
successfully applied for human plasma assay.
2.MaterialsandMethods
2.1. Chemicals and Reagents. PIO, GLP, REP, and Metformin
(IS) were obtained from Macleoids Pharmaceuticals Ltd.,
Mumbai, India. GLC, GLB were obtained from Medley
Pharmaceuticals, Diu and Daman, India. ROS and GLM
were obtained from Orchid Chemicals and Pharmaceuticals,
Chennai, India. NGL was obtained from Divis Pharmaceuti-
cals,Hyderabad,Indiawithmorethan99%purity. Methanol
(Qualigens, Mumbai, India) HPLC grade was used. SPE
cartridges (Oasis HLB 3mL, 60mg, Waters, Milford, MA,
USA) were used. All the reagents used were of analytical
reagent grade. Milli-Q water (Millipore Q-Gard) was used
throughout the analysis.
2.2. Instrumentation. The HPLC system consisted of Shi-
madzu (Kyoto, Japan) Class LC-10AT vp and LC-20AD
pumps connected with SPD-10A vp UV-Visible detector.
The data acquisition was performed by Spincotech 1.7
version software (Spinco Biotech Ltd., Chennai, India) and
monitored at a wavelength of 234nm. Samples were injected
using 25μL Hamilton syringe.
2.3. Chromatographic Conditions. A reverse phase Onyx
monolithic C18 column (100 × 4.6mm i.d., 5μm, Phe-
nomenex, Torrance, USA) was used for separation. The
mobile phase consisted of 0.05% formic acid in water asISRN Pharmaceutics 3
Table 1: Results of the linearity, LLOQ, and system suitability parameters (n = 3).
Compound λmax LLOQ (ng/mL) r2 tr k  Rs Tf W(5%) N HETP (mm)
ROS 245 24 0.9983 3.14 2.31 — 1.17 0.2876 9945 0.0101
PIO 265 36 0.9981 4.58 4.59 2.42 1.09 0.2912 9233 0.0108
GLP 270 35 0.9989 7.46 2.17 5.52 1.34 0.2764 10637 0.0094
GLC 225 30 0.9990 8.95 2.72 3.14 1.27 0.2819 7425 0.0135
REP 245 20 0.9987 12.17 3.11 7.01 1.25 0.3011 9910 0.0101
NGL 231 20 0.9989 14.39 2.79 3.47 1.42 0.3082 8941 0.0112
GLB 228 40 0.9978 16.32 2.09 7.46 1.37 0.2941 10003 0.0099
GLM 246 38 0.9987 18.78 2.57 2.89 1.28 0.2659 9081 0.0110
tr: retention time; k : capacity factor; Rs: resolution; Tf : tailing factor; W5%: width of peak at 5%; N: theoretical plates (USP); HETP: height equivalent to
theoretical plate Length of the column (mm)/theoretical plates.
Table 2: Summary of precision and accuracy from QC samples in plasma (n = 6).
Compound Spiked concentration Intraday Interday
(ng/mL) Mean ±SD %RSD Nominal (%) Mean ±SD % RSD Nominal (%)
53.7 53.4 ±3.7 6.93 99.4 53.0 ±3.6 6.79 98.6
ROS 489.2 481.6 ±19.9 4.13 98.4 481.9 ±20.7 4.29 98.5
1531.0 1520.5 ±129.5 8.51 99.3 1521.7 ±117.8 7.74 99.3
48.9 48.6 ±3.5 7.20 99.4 48.1 ±2.9 6.02 98.3
PIO 491.2 490.5 ±16.2 3.30 99.8 492.0 ±15.9 3.23 100.1
1513.8 1492.3 ±132.9 8.90 98.5 1497.0 ±125.6 8.39 98.8
50.6 52.1 ±3.3 6.33 102.9 50.9 ±4.0 7.85 100.6
GLP 492.3 504.7 ±18.9 3.74 102.5 499.3 ±19.9 3.98 101.4
1498.5 1506.1 ±109.2 7.25 100.5 1500.1 ±130.2 8.67 100.1
46.8 48.2 ±3.9 8.09 102.9 48.2 ±4.1 8.50 102.9
GLC 486.7 492.9 ±15.8 3.20 101.2 490.8 ±18.5 3.76 100.8
1467.0 1479.0 ±119.2 8.05 100.8 1475.6 ±125.6 8.51 100.5
49.2 51.1 ±2.9 5.67 103.8 48.9 ±3.8 7.77 99.3
REP 493.4 486.8 ±15.9 3.26 98.6 487.1 ±17.3 3.55 98.7
1502.7 1489.4 ±123.7 8.30 99.1 1486.9 ±91.7 6.16 98.9
52.9 51.7 ±3.1 5.99 97.7 51.5 ±3.0 5.82 97.4
NGL 478.6 492.5 ±17.2 3.49 102.9 490.2 ±16.9 3.44 102.4
1439.6 1452.4 ±134.1 9.23 100.9 1442.3 ±121.3 8.41 100.1
45.7 45.4 ±3.2 7.04 99.3 44.9 ±4.1 9.13 98.2
GLB 478.5 481.3 ±28.8 5.98 100.6 479.6 ±20.9 4.35 100.2
1452.0 1450.3 ±110.1 7.58 99.8 1451.9 ±97.9 6.74 99.9
48.6 49.1 ±2.9 5.90 101.0 48.5 ±3.5 7.21 99.7
GLM 490.5 499.6 ±25.6 5.12 101.8 492.8 ±24.3 4.93 100.4
1477.5 1479.0 ±121.1 8.18 100.1 1470.8 ±115.9 7.88 99.5
solvent A and methanol as solvent B. A linear isocratic was
run at 0.5mL/min consisting of solvent A and B in the ratio
of 42:58v/v. The injection volume was 20μL.
2.4. Preparation of Standard and Sample Solutions. Stock
s o l u t i o no fR O S ,P I O ,G L PG L C ,R E P ,N G L ,G L B ,a n d
GLM was prepared individually by dissolving 25mg of
each drug in methanol and diluted to 25mL to get a ﬁnal
concentration of 1000μg/mL. A series of working standard
solutions were prepared by transferring appropriate quantity
in order to get a calibration range of 50, 100, 500, 1000, 1500,
and 2000ng/mL by using methanol. IS was prepared at a
concentration of 1000ng/mL in methanol.
2.5. Extraction of Drugs from Plasma. Solid-phase extraction
was used to preconcentrate the analytes from the human
plasma. All the samples were extracted from human plasma
using Oasis HLB 3mL, 60mg (Waters, Milford, MA, USA),
solid-phase extraction cartridges. Each cartridge was equi-
librated and conditioned by acetonitrile, ultra pure water
of 1mL each. Samples were added to plasma and vortex-
mixed for 3min. Thereafter, the sample was loaded onto4 ISRN Pharmaceutics
Table 3: Stability data for anti-diabetic drugs in plasma.
Drug Nominal concentration Sample conditions (mean ±S.D)
ng/mL Short-terma Long-termb Freeze-thawc
Nominal (%) RSD Nominal (%) RSD Nominal (%) RSD
ROS 53.7 103.1 6.2 97.5 8.6 102.4 7.1
1531.0 99.3 2.0 98.0 2.2 98.7 1.7
PIO 48.9 102.0 5.9 97.1 8.8 100.6 5.9
1513.8 99.0 2.0 97.2 1.9 99.1 1.8
GLP 50.6 98.9 7.6 95.6 8.0 97.1 6.6
1498.5 99.3 1.5 98.7 1.4 99.8 0.9
GLC 46.8 105.7 8.7 99.6 3.4 100.1 2.3
1467.0 97.8 2.0 97.3 4.1 98.1 4.5
REP 49.2 107.8 8.9 99.2 3.8 99.2 3.0
1502.7 103.5 6.1 98.1 0.8 98.6 1.4
NGL 52.9 98.9 11.1 96.7 7.2 96.9 5.3
1439.6 108.0 6.4 99.0 4.8 98.5 2.8
GLB 45.7 95.4 13.2 95.1 10.6 95.5 7.8
1452.0 97.8 10.1 96.8 6.8 96.2 5.9
GLM 48.6 103.7 11.6 99.1 1.9 98.7 2.2
1477.5 106.3 6.0 98.7 2.3 98.6 1.0
aExposed at room temperature for 24h.
bStored at −70◦C.
cAfter three freeze-thaw cycles.
Table 4: Recovery of eight anti-diabetic drugs from plasma samples spiked with each drug spiked.
Compound Concentrations (ng/mL) % recovery and % RSD
LLOQ LQC MQC HQC LLOQ LQC MQC HQC
ROS 24.3 53.7 489.2 1531.0 80.1, 9.1 77.2, 11.3 81.5, 7.2 83.4, 6.9
PIO 36.1 48.9 491.2 1513.8 82.4, 7.3 80.6, 10.1 81.9, 8.1 82.3, 7.2
GLP 35.6 50.6 492.3 1498.5 80.9, 6.7 81.9, 14.7 82.3, 7.7 84.0, 9.8
GLC 30.5 46.8 486.7 1467.0 79.9, 5.9 84.5, 12.6 83.2, 11.1 79.7, 13.9
REP 20.2 49.2 493.4 1502.7 84.5, 4.9 80.8, 14.2 80.9, 8.7 82.4, 9.7
NGL 20.6 52.9 478.6 1439.6 80.8, 8.8 83.4, 13.7 82.1, 12.4 80.9, 10.6
GLB 40.1 45.7 478.5 1452.0 79.1, 10.3 75.5, 12.2 78.9, 12.7 76.8, 12.3
GLM 38.4 48.6 490.5 1477.5 81.2, 10.7 78.2, 11.0 80.1, 4.7 80.1, 10.
and passed through the cartridge without lab vacuum and
the analytes were then eluted with 1mL of acetonitrile. The
eluent was evaporated to dryness at 40◦Cu n d e ras t r e a m
of nitrogen. The dried extract was then reconstituted with
100μL of mobile phase, and a 20μL was injected into the
chromatographic system.
2.6. Method Validation. The proposed method was validated
in the light of FDA Guidelines for linearity, precision,
sensitivity and selectivity, stability and recovery [28, 29].
3. Results andDiscussion
3.1. Development and Optimization of Chromatographic Con-
ditions. Optimization of the chromatographic conditions
areintendedtotakeintoaccountthevariousgoalsofmethod
development and to weigh each goal (resolution, runtime,
sensitivity, peak symmetry, etc.) accurately, according to the
requirement of LC-MS and HPLC methods being used for
the estimation of drugs in biological ﬂuids.
Thedrugsarenot totallysolubleinwaterwhereassoluble
inorganicsolventslikemethanolandacetonitrile.Duringthe
development phase, the mobile phase containing acetonitrile
water resulted in asymmetric peaks with poor resolution and
greater tailing factor (>2) and high run time. The successful
use of mobile phase containing a mixture of 0.05% formic
acid and methanol in the ratio of 42:58v/v ﬁxed at the ﬂow
rate 0.5mL/min reduced tailing (<1.5) and resulted in good
peaksymmetryandresolution(>1.5).Methanolwasselected
because of its favorable UV transmittance, low viscosity, and
better solubility. The analytes were monitored at 234nm and
the retention times were found to be 3.14, 4.58, 7.46, 8.95,
12.17, 14.39, 16.32 and 18.78 min for ROS, PIO, GLP, GLC,
REP, NGL, GLB, and GLM, respectively, and IS was eluted at
2.36min (Figure 2).ISRN Pharmaceutics 5
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Figure 2: (a) Chromatogram showing blank, (b) chromatogram showing anti-diabetic drugs at LLOQ concentration levels, and (c)
chromatogram showing drugs at 1000ng/mL extracted from human plasma (1) ROS, (2) PIO, (3) GLP, (4) GLC, (5) REP, (6) NGL, (7)
GLB, and (8) GLM.
3.2. Validation of the Developed Method
3.2.1. Linearity and Calibration Curve. The linearity was
tested at the concentration range of 50–2000ng/mL and
the calibration curve constructed was evaluated by its
correlation coeﬃcient. The correlation coeﬃcient (r2)f o ra l l
the calibration curves was consistently greater than 0.9984 ±
0.0006 (Table 1).
3.2.2. Method Sensitivity and Speciﬁcity. Within the same 30-
min LC run, all the drugs at 50ng/mL each under investiga-
tion could be easily detected from human plasma matrices
(n = 10). Conﬁrmation of these drugs could be readily
achieved by comparing the retention times obtained from
thesample withthose oftheircorresponding drug standards.
The lower limit of quantiﬁcation (LLOQ) (Table 1)w a s
deﬁned as the lower concentration that could consistently
produce accurate and precise chromatogram that could
be quantiﬁed. Figure 2-b shows the chromatogram of the
drugs obtained from plasma and samples spiked with the
concentration at LLOQ.
The method speciﬁcity was assessed with diﬀerent
plasma samples (n = 30 each, each from diﬀerent plasma
sources) analyzed with the described method. Interferences
from the matrices at the targeted retention times were not
observed.
3.2.3. Precision and Accuracy. The intraday precision (ex-
pressed by coeﬃcient of variation of replicate analyses) was
estimated on the three quality control levels and the interday
precision on the nine calibration standard levels. Table 2
shows the results obtained for the intraassay (variation
intraday) and inter-assay (variation inter-day) precision for
drugs.Theprecisionforalltheseanalytesunderinvestigation
did not exceed 15% at any of the concentrations studied and
well met the requirements of validation.
3.2.4. Stability. The stability of samples reconstituted after
extraction from plasma (as in experimental section) was
investigated under various storage conditions. Short-term
stability was studied at room temperature for 8h, long-
term stability studies were done at −70◦Cf o r3 0 d ,a n d
freeze-thaw stability was also evaluated by successive cycles
of freezing and thawing the samples by storing at −70◦C
and room temperature, respectively. Three complete freeze-
thaw cycles were performed. They were carried out at two
concentration levels (low and high QC) at six replicates. The
percentage stability was estimated by comparing the mean of
back calculated concentrations of all analytes from the stored
stability samples with that of freshly spiked QC samples. The
results indicated that each analyte had an acceptable stability
under those conditions, as shown in Table 3.
3.3. Recovery of Drugs from Human Plasma. Solid-phase
extraction technique was found to be successful in extraction
of eight anti-diabetic drugs from human plasma and the
recovery was determined by comparing peak areas of spiked
plasma extracts with those of unextracted neat standards
freshly prepared in methanol. Plasma samples (n = 6) spiked
with the analytes at their respective LLOQ, low, middle
and high QC levels were analyzed. The area ratios of the
targeted drugs were compared with those obtained from
blank extracts spiked with the 8 target drugs after extraction
(taken as 100% recovery of the drug from that particular
matrix). Recoveries of the drugs are summarized in Table 4.6 ISRN Pharmaceutics
4. Conclusion
A simple, speciﬁc, selective, and precise method was devel-
oped for the determination of anti-diabetic drugs ROS, PIO,
GLP, GLC, REP, NGL, GLB, and GLM. The mobile phase is
economicalandsimpletopreparewithlittleornovariations.
The run time 30min indicates short analysis time. The sam-
ple recoveries in human plasma were in good agreement and
they suggested no interference in the estimation. Hence, this
method can be easily and conveniently used for the routine
analysis of the drug in plasma samples for pharmacokinetic
studies.
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